MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41423-026-01395-x

Медицинская библиотека · Cellular & molecular immunology · 2026

Tofacitinib repairs inflammation and mitochondrial dysregulation in GM-CSF-reprogrammed RA macrophages.

Satoeya Neha, Zack Stephanie R, Zoubi Osama Al, Umar Sadiq, Burgos Adel, Abdulrab Sara, Zanotti Brian, Volin Michael V, Karam Joseph A, Xia Yinglin, Umali Diana C, Arami Shiva, Al-Awqati Mina, Chang Huan T, O'Neill Luke A J, Schett Georg, Sweiss Nadera, Shahrara Shiva

СтатьяПоддержка NIH: внешняя программаПоддержка правительства СШАПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Rheumatoid arthritis (RA) exhibits heterogeneous endotypes, complicating treatment strategies. GM-CSF and GM-CSFRα are enriched in RA synovial CD68⁺macrophages (MΦs), and are implicated in acute and chronic disease stages. Since anti-TNFi and anti-IL6R therapies did not effectively suppress GM-CSF/GM-CSFRα expression or the GM-CSF-associated landscape, we explored alternative therapeutic strategies to target GM-CSF function using RA blood, synovial tissues, and preclinical models. We demonstrate that GM-CSF-MΦs reprogrammed in RA blood and synovial tissue share a distinct IL1β⁺S100A⁺HIF1⁺IL10ˡᵒNFIL3/6ˡᵒ expression profile, manifested by mitochondrial oxidative stress and fragmentation. To correct the metabolic imbalance of GM-CSF-MΦs, cells were treated with a complex I inhibitor (i) or a glucose uptake blocker. Complex Ii did not broadly alter the inflammatory or metabolic networks or affect the mitochondrial dynamics remodeled by GM-CSF-MΦs. While the glucose uptake inhibitor (HK2i) reduced glycolysis-derived ATP, it had limited efficacy in restricting the inflammatory signature or restoring TCA enzymes in GM-CSF-MΦs. In contrast, tofacitinib achieved broad-spectrum effects by downregulating GM-CSFRα expression and inhibiting STAT5 signaling. Moreover, tofacitinib redirected RA blood and synovial IL1β⁺S100A⁺HIF1⁺IL10ˡᵒNFIL3/6ˡᵒMΦs into a regulatory phenotype, reversing oxidative stress and mitochondrial fragmentation. In preclinical models, local GM-CSF overexpression induced MΦ-directed joint inflammation and metabolic dysregulation. Consistently, Tofacitinib reversed GM-CSF-differentiated murine IL1β⁺HBEGF⁺HIF1⁺MΦs by impeding STAT5 signaling, correcting metabolic dysregulation, and repairing mitochondrial fragmentation. In conclusion, anti-TNFi, anti-IL6R, and metabolic-targeted therapies were largely ineffective in modifying GM-CSF-MΦ pathology. Conversely, tofacitinib deactivation of STAT5 attenuates GM-CSF-MΦ-triggered inflammation and mitochondrial malfunction by restoring regulatory markers and rebalancing oxidative phosphorylation in RA specimens and/or preclinical models.

Для цитирования: Satoeya Neha, Zack Stephanie R, Zoubi Osama Al, Umar Sadiq, Burgos Adel, Abdulrab Sara, Zanotti Brian, Volin Michael V, Karam Joseph A, Xia Yinglin, Umali Diana C, Arami Shiva, Al-Awqati Mina, Chang Huan T, O'Neill Luke A J, Schett Georg, Sweiss Nadera, Shahrara Shiva. Tofacitinib repairs inflammation and mitochondrial dysregulation in GM-CSF-reprogrammed RA macrophages.. Cellular & molecular immunology. 2026. DOI: 10.1038/s41423-026-01395-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.